Proteomic and Functional Analyses Reveal a Mitochondrial Dysfunction in P301L Tau Transgenic Mice*

Received for publication, January 11, 2005, and in revised form, April 13, 2005
Published, JBC Papers in Press, April 14, 2005, DOI 10.1074/jbc.M500356200

Della C. David‡, Susanne Hauptmann§§, Isabel Scherping§§, Katrin Schuessel§, Uta Reil§, Patrizia Rizzu, Rivka Ravid**, Stefan Droese‡‡, Ulrich Brandt‡‡, Walter E. Muller§, Anne Eckert§§, and Jürgen Götz‡‡‡

From the ‡Division of Psychiatry Research, University of Zurich, 8008 Zurich, Switzerland, and §Department of Pharmacology, Biocentre, University of Frankfurt, 60439 Frankfurt, Germany, †Department of Human Genetics, Section of Medical Genomics and Center for Neurogenomics and Cognitive Research, VU University Medical Center and VU University, 1081 BT Amsterdam, The Netherlands, **The Netherlands Brain Bank, 1105 AZ Amsterdam, The Netherlands, ‡§Center for Biological Chemistry, University of Frankfurt, 60590 Frankfurt, Germany, and §§Neurobiology Research Laboratory, Psychiatric University Clinic, 4025 Basel, Switzerland

Transgenic mice overexpressing the P301L mutant human tau protein exhibit an accumulation of hyperphosphorylated tau and develop neurofibrillary tangles. The consequences of tau pathology were investigated here by proteomics followed by functional analyses. Mainly metabolism-related proteins including mitochondrial respiratory chain complex components, antioxidant enzymes, and synaptic proteins were identified as modified in the proteome pattern of P301L tau mice. Significantly, the reduction in mitochondrial complex V levels in the P301L tau mice revealed using proteomics was also confirmed as decreased in human P301L FTDP-17 (frontotemporal dementia with parkinsonism linked to chromosome 17) brains. Functional analysis demonstrated a mitochondrial dysfunction in P301L tau mice together with reduced NADH-ubiquinone oxidoreductase activity and, with age, impaired mitochondrial respiration and ATP synthesis. Mitochondrial dysfunction was associated with higher levels of reactive oxygen species in aged transgenic mice. Increased tau pathology as in aged homozygous P301L tau mice revealed modified lipid peroxidation levels and the up-regulation of antioxidant enzymes in response to oxidative stress. Furthermore, P301L tau mitochondria displayed increased vulnerability toward β-amyloid (Aβ) peptide insult, suggesting a synergistic action of tau and Aβ pathology on the mitochondria. Taken together, we conclude that tau pathology involves a mitochondrial and oxidative stress disorder possibly distinct from that caused by Aβ.

Alzheimer disease (AD) is characterized by two major histopathological hallmarks, extracellular plaques of fibrillar β-amyloid (Aβ) peptides and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein (1, 2). Mutations in tau have been identified in a related neurodegenerative disorder called frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) with NFT formation in the absence of plaque formation (3–5). Transgenic mice overexpressing the P301L mutant human tau protein were created to model tauopathies in vivo (6, 7). These mice show an accumulation of hyperphosphorylated tau and NFT formation similar to those in FTDP-17 and AD.

Little is known about the distinct intracellular mechanisms underlying the consequences of tau pathology. This insight could help us to understand the selective vulnerability of cells with tau pathology and thereby the pathogenesis of AD. Increasing evidence highlights a connection between AD and mitochondrial dysfunction together with a deregulation of energy metabolism and oxidative stress (8). Various reports have demonstrated markedly reduced levels of mitochondrial proteins and activities (9–11), increased glucose turnover (12, 13), increased mitochondrial DNA mutations (14–16), and increased lipid peroxidation (17–19) in AD brains.

To examine the contribution of tau to these neurodegenerative processes, we carried out a proteomic analysis of our P301L tau transgenic mice. To zoom in on proteins relevant to the pathology, we sequentially extracted whole brains from six pairs of P301L tau and wild-type (WT) mice into three fractions according to protein solubility. Comparative analysis of two-dimensional gels run for each fraction revealed statistically significant differences between P301L tau and WT mice. We found three principal categories of proteins differentially regulated by P301L tau expression: metabolism-related proteins including mitochondrial respiratory chain complex components, oxidative stress-related enzymes implicated in reactive oxygen species (ROS) detoxification, and synapse-related pro-

tofrontotemporal dementia with parkinsonism linked to chromosome 17; NFT, neurofibrillary tangle; Aβ, β-amyloid; WT, wild-type; ROS, reactive oxygen species; GST, glutathione S-transferase; SOD, superoxide dismutase; GR, glutathione reductase; Drp, dynamin-related protein; MALDI, matrix-assisted laser desorption ionization; TOF/TOF, tandem time-of-flight; MDA, malondialdehyde; DBQ, α-dehydroquinone; FCCP, carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone; HAR, hexamethylenethiourea(III)-chloride; CHAPS, 3-[3-cholamidopropyl]dimethylammonio]-1-propanesulfonic acid; DHE, dihydroethidium; H2DCF-DA, 2'-7'-dichlorodihydrofluorescein diacetate; PIPEPS, 1,4-piperazinediethanesulfonic acid; MOPS, 4-morpholinepropanesulfonic acid; ANOVA, analysis of variance; IPG, immobilized pH gradient.

This paper is available on line at http://www.jbc.org

23802

This is an Open Access article under the CC BY license.
Mitochondrial Dysfunction in P301L Tau Transgenic Mice

23803

Proteins. Consistent with these findings, P301L tau mice exhibited mitochondrial functional defects together with reduced electron transport chain complex I activity. Aged P301L tau mice showed impaired mitochondrial respiration, reduced complex V activity, and higher levels of ROS than WT controls. Furthermore, modified lipid peroxidation and increased antioxidant enzyme activities were detected in aged homozygous mice. We also found an increased vulnerability of P301L tau mitochondria to Aβ insult, suggesting a synergistic action of tau and Aβ pathology on the mitochondria. Corroborating the P301L tau mouse mitochondrial deficits, we could demonstrate a reduction in complex V levels in human P301L FTDP-17 brains, implying a potential mitochondrial dysfunction in human patients afflicted with this neurodegenerative disorder.

EXPERIMENTAL PROCEDURES

Transgenic Mice—The transgenic mice used in the present study express the human pathogenic mutation P301L of tau together with the longest human brain tau isoform (htau40) under control of the neuron-specific 3′R promoter (7). This isoform contains exons 2 and 3 as well as four microtubule-binding repeats (2′-3′-4R, human tau40). Proto- nuclear injections were done into C57Bl/6 x DBA2 F2 oocytes to obtain founder animals that were back-crossed with C57Bl/6 mice to establish transgenic lines. In addition, homozygous P301L tau mice were obtained and confirmed by TaqMan real-time quantitative PCR (data not shown).

Different age sets of mice were used for different experimental procedures corresponding to various stages in the development of tau pathology. P301L tau mice show tau hyperphosphorylation already at 3 months (7). NFT formation starts at 6 months of age (20). We used 8.5-10-month-old mice for the proteomics analysis to study the consequences of tau pathology at the beginning of NFT formation without the influence of aging. At a similar age (i.e. 12 months old), mitochondrial membrane potential and complex I activity were determined at maximum ATP levels, mitochondrial respiration, and ROS levels were analyzed in mice at 12 and 24 months of age. 24-month-old mice are expected to bear the highest levels of tau pathology. 18-month-old mice were used to determine mitochondrial numbers in neurites. This intermediate age allows us to see the full effect of tau pathology on mitochondrial transport without pronounced aging effects as those seen in 24-month-old mice. Finally, 12- and 24-month-old homozygous, hemizygous, and wild-type mice were tested for lipid peroxidation.

Sequential Extraction of Brain Samples—Four pairs of 8.5-month-old male hemizygous P301L tau and WT control mice and two pairs of 10-month-old male hemizygous P301L tau and WT control mice were sacrificed by cervical dislocation and brains were removed at 4 °C and snap-frozen in liquid nitrogen. Brains were sequentially extracted with the three-step procedure (4): (1) nuclear fraction and (2) mitochondrial fraction containing all the cytoplasmic contaminants. The bound peptides were eluted directly onto the MALDI target with 0.8 μl of α-cyano-4-hydroxycinnamic acid matrix (5 mg/ml) in 65% acetonitrile, 35% double-distilled H2O containing 0.1% trifluoroacetic acid. Digests were analyzed by MALDI tandem time-of-flight (TOF/ TOF) mass spectrometry using a 4700 Proteomics Analyzer MALDI-TOF/TOF mass spectrometer (Applied Biosystems). One mass spectrum along with tandem mass spectra of all precursors and minimum signal/noise ratio of 80 were recorded for each sample spot. Autoproteolytic fragments of trypsin were used as internal calibrants in the mass spectrometry mode. The mass and tandem mass spectra were analyzed using Mascot (Matrix Science, London, UK; available at www.matrixscience.com) as the search engine. A combined mass spectrometry and tandem mass spectrometry search with a peptide tolerance of 0.25 ppm and a fragment tolerance of 0.7 Da was carried out against the UniProt complete mouse proteome data base (available at ftp://ftp.ebi.ac.uk/pub/databases/integ8). Protein identification was considered significant if the Mascot score was higher than the probability p < 0.05 of a random match.

Evaluation of Complex V Level in Human Brains—Hemizygous female human temporal cortex of two transgenic and four P301L FTDP-17 patients were prepared in 150 mM Tris, pH 6.8, 2.5% SDS, 8 μM urea, 20% glycerol, 10% β-mercaptoethanol, and 0.1% bromphenol blue and subjected to Western blotting using standard methods. 2.5 μl of total brain lysate were loaded. The blots were developed with antibodies directed against the complex V component ATP synthase chain D (A21343, 0.2 μg/ml; Molecular Probes) and against porin for normalization (A31855, 0.2 μg/ml; Molecular Probes). As a secondary antibody, a goat anti-mouse IgG (Amersham Biosciences, L5000) was used. Non-overexposed films were used to quantify the bands with Image J software (National Institutes of Health; available at rsb.info.nih.gov/ij/). Complex V levels were expressed as a percentage of porin levels.

Samples used (as loaded) were as follows: 1) control brain, 73-year-old female; 2) control brain, 72-year-old male; 3) P301L brain, 64-year-old male; 4) P301L brain, 52-year-old male; 5) P301L brain, 66-year-old male; and 6) P301L brain, 60-year-old male. Three other control samples were used (specifically, control temporal cortex from 78-year-old female, 82-year-old female, and 78-year-old male brains) (data not shown).

Materials Used for Mitochondrial Analysis—Rhodamine 123, tetra- methylrhodamine-ethylamine-ethanolamine (MitoTracker Green FM) were purchased from MitoProbes Europe (Leiden, The Netherlands); 2′,7′- dichlorodihydrofluorescein diacetate (H2DCF-DA) and dihydroethidium (DHE) were purchased from Calbiochem (Merck Biosciences, Bad Soden, Germany); hydrochloric acid, ethanol, ferric chloride, and chloroform were purchased from VWR International (Darmstadt, Germany); and the Vitalight HT kit was purchased from Cambrex Bio Science (Copenhagen, Denmark). The Cytochrome c Oxidase (Complex IV) as-
Mitochondrial Dysfunction in P301L Tau Transgenic Mice

Determination of the Mitochondrial Membrane Potential φm—The membrane potential of the inner mitochondrial membrane was measured using Rhodamine 123 dye added to the cell culture medium at a final concentration of 0.4 μM for 15 min. Cells were washed twice with Hank’s balanced salt solution (Sigma), and fluorescence was determined with a Victor2 plate reader (PerkinElmer Life Sciences) at 490 nm (excitation)/535 nm (emission). Loading capacity of the dye or incubated with Aβ_1-42, all aqueous solutions were prepared with deionized and filtered water (Millipore).

Brain Tissue Preparation for Mitochondrial Analysis—Mice (8 pairs of 12-month-old and 8 pairs of 24-month-old hemizygous P301L tau and WT control mice) were sacrificed by decapitation, and brains were quickly dissected on ice (described in Ref. 22, with modification). After removing the cerebellum, one hemisphere (the other hemisphere was directly used for preparation of isolated mitochondrial) was minced into 1 ml of medium I (138 mM NaCl, 5.4 mM KCl, 0.17 mM Na2HPO4, 0.22 mM K2PO4, 5.5 mM glucose, and 58.4 mM sucrose, pH 7.35) with a scalpel and further dissociated by trituration through a nylon mesh (pore diameter, 1 mm) with a Paster pipette. The resulting suspension was filtered by gravity through a fresh nylon mesh with a pore diameter of 102 μm, and the dissociated cell aggregates were washed twice with medium II (110 mM NaCl, 5.3 mM KCl, 1.8 mM CaCl2, 0.8 mM MgCl2, 6 mM H2O, 25 mM glucose, 70 mM sucrose, 20 mM HEPES, 1 mM EDTA, 0.45% bovine serum albumin, 0.5 mM dithiothreitol, pH 7.4) by centrifugation (680 g for 3 min at 4 °C). 100 μl of the suspension were used for protein determination. After centrifugation, cells were resuspended in 3 ml of Dulbecco’s modified Eagle’s medium, and then aliquots (100 μl/well) were distributed in a white 96-well plate for measurement of ATP levels, and aliquots (250 μl/well) were distributed in a 48-well plate for measurement of the mitochondrial membrane potential and ROS levels. The latter were maintained at 37 °C in a humidified atmosphere of 5% CO2/95% air for the staining period with the appropriate dye or incubated with Aβ for 4 h. The preparations of cortical cells from P301L tau transgenic mice and WT littermate controls (crossover design) were made within 2 h under the same conditions and in parallel. Data are expressed as fluorescence units per mg/ml protein. The total protein content was determined (25).

ATP Levels—ATP levels were determined with a bioluminescence assay (ViaLight HT; Cambrex Bio Science). The enzyme luciferase, which catalyzes the formation of light from ATP and luciferin, was utilized. The emitted light was linearly related to the ATP concentration and measured using a luminometer (26).

ROS Levels—Levels of cytosolic ROS were measured using the fluorescent probe H2DCF-DA, and levels of superoxide anion radical were measured by using DHE. Brain cells were loaded for 15 min with 10 μM H2DCF-DA or 10 μM DHE. After washing twice with Hank’s balanced salt solution, formation of the fluorescent product dichlorofluorescein was detected with Victor2 multiplate reader (PerkinElmer Life Sciences) at 485 nm (excitation)/535 nm (emission). Dichlorofluorescein is trapped mainly in the cytoplasm and oxidized by several ROS, most notably hydrogen peroxide (27). DHE, which is oxidized to the fluorescent ethidium cation by O2, was detected with Victor2 multiplate reader at 490 nm (excitation)/590 nm (emission) (28).

Amount of Mitochondria—The total amount of mitochondria was measured using the cell-permeable mitochondrial-selective dye Mitotracker Green FM (100 nm, 15 min) which is essentially nonfluorescent in aqueous solutions and only becomes fluorescent once it accumulates in the lipid environment of mitochondria (490 nm, excitation; 518 nm, emission). To determine the number of mitochondria, in addition, four pairs of 18-month-old P301L tau transgenic and WT mice were perfused transcardially with 4% paraformaldehyde in microtubule stabilization buffer (65 mM Pipes, 25 mM HEPES, 10 mM EGTA, and 3 mM MgCl2, pH 6.9). 5-μm paraffin brain sections were co-immunostained with anti-porin (A31855, diluted 1:2000; Molecular Probes) and anti-tubulin (YOL 1/34, 1:600; Abcam Limited, Cambridge, UK) antibodies, followed by incubation with Cy3- and Cy2-conjugated secondary antibodies (Jackson Immunoresearch, Milan Analytic, Fribourg, Switzerland). The number of mitochondria in neurites of CA1 hippocampal neurons was counted both proximal and distal to the cell body.

Preparation of Isolated Mitochondria—Mice were sacrificed by decapsulation, and one brain hemisphere was rapidly dissected on ice and washed in an ice-cold buffer (210 mM mannitol, 70 mM sucrose, 10 mM HEPES, 1 mM EDTA, 0.45% bovine serum albumin, 0.5 mM dithiothreitol, and Complete protease inhibitor mixture tablets (Roche Diagnostics)). After removing the cerebellum, the tissue sample was homogenized in 2 ml of buffer with a glass homogenizer (10–15 strokes, 400 rpm), and the resulting homogenate was centrifuged at 1400 g for 7 min at 4 °C to remove nuclei and tissue particles. The low-speed centrifugation step was repeated once with the supernatant. Then, the supernatant fraction was centrifuged at 10,000 g for 5 min at 4 °C to pellet mitochondria. The resulting pellet was resuspended in 1 ml of ice-cold buffer and centrifuged again at 800 g for 5 min at 4 °C to obtain a mitochondrial fraction. This fraction was resuspended in 100 μl of ice-cold buffer and stored at 4 °C until use, followed by determination of protein content (23).

Mitochondrial Respiration—The rate of mitochondrial respiration was monitored at 25 °C using an Oxygraph-2k system (Oroboros, Innsbruck, Austria) equipped with two chambers and DatLab software. Mitochondria (0.5 mg) were added to 2 ml of a buffer containing 65 mM sucrose, 10 mM potassium phosphate, 10 mM Tris-HCl, 10 mM MgSO4,
Mitochondrial Dysfunction in P301L Tau Transgenic Mice

Proteins involved in mitochondrial respiration and metabolism

NADH-ubiquinone oxidoreductase 30-kDa subunit
ATP synthase D chain
ATP synthase D chain
Triosephosphate isomerase
Inorganic pyrophosphatase (2010317E03Rik protein)
Malate dehydrogenase, cytoplasmic

Proteins involved in oxidative stress

 Peroxiredoxin 6
Thioredoxin-dependent peroxide reductase (perioxidin 3)
GSTP2
GSTMu 1
Phospholipid hydroperoxide glutathione peroxidase

Synapse-related proteins

DRP-2
DRP-2
DRP-2
DRP-2
DRP-3
Synapsin 1
Synapsin 1
Septin 11
Septin 5 (CDCrel-1)

Other proteins

Stathmin
MSTII (stress-induced phosphoprotein 1)
Stress-induced phosphoprotein 1
γ-Soluble NSF attachment protein (γ-SNAP)
Endoplasmic reticulum protein Erp29 precursor
Endoplasmic reticulum protein Erp29 precursor
Lipoamide acyltransferase component of branched-chain
α-keto acid dehydrogenase complex
β-Alanine oxoglutarate aminotransferase homologue (GABA transaminase)

Mus musculus adult male kidney cDNA; gene name; ethel1, synonym: heco
Probable α-tyrosyl-tRNA deacylase
GRB2 adapter protein
Lamin A and C2
Lamin A
Paraspeckle protein 1
Myeloid leukemia factor 2
UPF0082

| Protein | Accession no. | Fraction | Spot no. | Fold difference | Student’s t test | Mascot score |
|---------|---------------|----------|----------|-----------------|-----------------|--------------|
| NADH-ubiquinone oxidoreductase 30-kDa subunit | Q9DCT2 | E2 | 375 | −1.62 | 0.0089 | 101 |
| ATP synthase D chain | Q9DCX2 | E2 | 455 | −1.90 | 0.0124 | 134 |
| ATP synthase D chain | Q9DCX2 | E2 | 1457 | −1.66 | 0.0026 | 62 |
| Triosephosphate isomerase | P17751 | E2 | 750 | −1.79 | 0.0139 | 71 |
| Inorganic pyrophosphatase (2010317E03Rik protein) | Q9DS19 | E1 | 576 | 1.56 | 0.0007 | 218 |
| Malate dehydrogenase, cytoplasmic | P14152 | E1 | 323 | −1.58 | 0.0096 | 63 |
| Peroxiredoxin 6 | O08709 | E2 | 38 | −1.90 | 0.0076 | 287 |
| Thioredoxin-dependent peroxide reductase (perioxidin 3) | P20108 | E2 | 978 | −1.76 | 0.0007 | 91 |
| GSTP2 | P19157 | E2 | 443 | −1.68 | 0.0104 | 158 |
| GSTMu 1 | P16049 | E2 | 622 | −1.61 | 0.0145 | 182 |
| Phospholipid hydroperoxide glutathione peroxidase | O70255 | E1 | 1605 | −1.57 | 0.0168 | 98 |
| Stathmin | P54227 | E1 | 2156 | −1.66 | 0.0081 | 55 |
| MSTII (stress-induced phosphoprotein 1) | Q60864 | E2 | 1741 | 1.53 | 0.0064 | 101 |
| Stress-induced phosphoprotein 1 | Q9GL66 | E2 | 140 | 1.59 | 0.0000 | 133 |
| γ-Soluble NSF attachment protein (γ-SNAP) | Q9CW27 | E3 | 337 | 1.52 | 0.0048 | 491 |
| Endoplasmic reticulum protein Erp29 precursor | P57759 | E2 | 778 | −2.08 | 0.0058 | 134 |
| Endoplasmic reticulum protein Erp29 precursor | P57759 | E2 | 582 | −1.72 | 0.0112 | 100 |
| Lipoamide acyltransferase component of branched-chain | P53395 | E2 | 1893 | 1.50 | 0.0126 | 87 |
| α-keto acid dehydrogenase complex | Q8BZ3A | E2 | 240 | −1.71 | 0.0107 | 74 |
| β-Alanine oxoglutarate aminotransferase homologue (GABA transaminase) | Q9DCM0 | E2 | 782 | −1.56 | 0.0137 | 71 |
| Mus musculus adult male kidney cDNA; gene name; ethel1, synonym: heco | Q9DD18 | E1 | 251 | −1.71 | 0.0004 | 131 |
| Probable α-tyrosyl-tRNA deacylase | Q60631 | E2 | 1213 | −1.57 | 0.0100 | 122 |
| Lamin A and C2 | P11516 | E2 | 1207 | 1.86 | 0.0075 | 203 |
| Lamin A | P48678 | E2 | 1207 | 1.86 | 0.0075 | 203 |
| Paraspeckle protein 1 | Q8R326 | E2 | 1207 | 1.86 | 0.0075 | 196 |
| Myeloid leukemia factor 2 | Q99KX1 | E2 | 1609 | 1.56 | 0.0190 | 83 |
| UPF0082 | Q90KZ7 | E1 | 178 | 1.58 | 0.0086 | 135 |

*SWISS-PROT/TrEMBL accession number.
 Sequential extraction fraction where the protein was identified.
 Mascot protein identification score is = 10^-Log (P), where P is the probability that the observed match is a random event. Protein scores greater than 57 are significant (p < 0.05), as based on the mouse database used here.
 This spot was independently identified twice as stathmin with a Mascot score near to significance. Tandem mass spectra were manually validated, and the identification was considered correct.

Mitochondria were solubilized in n-dodecyl β-D-maltoside (20%) (Sigma-Aldrich). NADH:hexaammineruthenium(III)-chloride (HAR) activity was measured at 30 °C in a buffer containing 2 mM Na’/MOPS, 50 mM NaCl, and 2 mM KCN, pH 7.2, using 2 mM HAR and 200 μM NADH as substrates to estimate the complex I content. To determine NADH-ubiquinone oxidoreductase activity, 100 μM n-decylubiquinone (DBQ) and 100 μM NADH were used as substrates, as described previously (29). Oxidation rates of NADH were recorded with a Shimadzu Multi Spec-1501 diode array spectrophotometer (ε_340–400 nm = 6.1 mM⁻¹ cm⁻¹). Complex I activity was normalized to the complex I content of the mitochondrial preparation and is given as DBQ/HAR ratio.

Complex IV Activity—Cytochrome c oxidase activity was determined in intact isolated mitochondria using the Cytochrome c Oxidase Assay Kit. The colorimetric assay is based on the observation that a decrease in absorbance at 550 nm of ferricytochrome c is caused by its oxidation to ferrocytochrome c by cytochrome c oxidase. The Cytochrome c Oxidase Assay was performed as described previously (30).
Mitochondrial Dysfunction in P301L Tau Transgenic Mice

Fig. 2. Reduced complex V levels in human P301L FTDP-17 brains. A, Western blot of human temporal cortex brain homogenates. Complex V (ATP synthase) is recognized as the top band using an anti-ATP synthase D chain antibody, and the mitochondrial protein marker porin is recognized as the bottom band using an anti-porin antibody. Control brain homogenates were loaded in lanes 1 and 2, and P301L FTDP-17 brain homogenates were loaded in lanes 3–6. B, complex V/porin percentages for control and P301L brains after Western blot band quantification. Sample percentages are represented in the same order as on the Western blot described in A.

method using the Lipid Peroxidation Assay Kit (Calbiochem) (31). The colorimetric reaction is a condensation of the aldehyde with 1-methyl-2-phenylindole, yielding a chromophore with an absorption maximum at 586 nm. Basal levels of MDA were assayed after incubation of samples for 30 min at 37 °C, and stimulated MDA levels were determined under the same conditions in the presence of 50 μM FeCl₃ in the sample homogenate.

Cu,Zn-SOD Activity—Cu,Zn-SOD (EC 1.15.1.1) activity was measured with the Superoxide Dismutase Assay Kit (Calbiochem) (32). To remove interfering substances and rule out Mn-SOD activity, Cu,Zn-SOD enzyme activity was assayed after an extraction procedure with chloroform and ethanol according to the supplier’s manual. SOD activity was calculated based on the Vₐ/Vₘ ratio of the auto-oxidation rates of the chromophore BXT-01050 measured at 37 °C in the presence (Vₐ) and absence (Vₘ) of sample. The chromophore was measured in a GeneSys 5 photometer (Spectronic Instruments, Rochester, NY) at 525 nm. 1 Cu,Zn-SOD activity unit is defined as the activity that doubles the auto-oxidation background (Vₐ/Vₘ = 2).

Glutathione Peroxidase Activity—Glutathione peroxidase (cytosolic glutathione peroxidase, EC 1.11.1.9) activity was measured using the Cellular Glutathione Peroxidase Assay Kit (Calbiochem) (33) and tert-butyldihydroperoxide as substrate. This reaction is based on the enzymatic reduction of hydroperoxide by glutathione peroxidase under consumption of reduced glutathione, which is restored from oxidized glutathione in a coupled enzymatic reaction by glutathione reductase (GR). GR reduces oxidized glutathione to reduced glutathione under consumption of NADPH as reducing equivalents. The decrease in absorbance at 340 nm due to NADPH consumption was measured in a Victor2 multplate reader using a 355-nm filter with 40 nm bandpass. 1 unit of glutathione peroxidase is defined as the activity that converts 2 μmol reduced glutathione/min at 25 °C.

GR Activity—The GR (EC 1.8.1.7) activity was determined using the Glutathione Reductase Assay Kit (Calbiochem) (34). The enzymatic activity was assayed photometrically by measuring NADPH consumption during the enzymatic reaction. In the presence of oxidized glutathione and NADPH, GR reduces oxidized glutathione and oxidizes NADPH to yield NADP, resulting in a decrease of absorbance at 340 nm, which was measured in a Victor2 plate reader. 1 unit of GR is defined as the activity that reduces 1 μmol oxidized glutathione (corresponding to 1 μmol NADPH/min at 25 °C).

Statistical Analysis—Data are represented as means ± S.E. For statistical comparison, Student’s t test, one-way ANOVA followed by Tukey’s post hoc test, or two-way ANOVA followed by Bonferroni post hoc tests was used. Only p values of < 0.05 were considered statistically significant.

RESULTS

Proteomic Analysis of P301L Tau Transgenic Mice—We performed a proteomic study to carry out an unbiased characterization of the consequences of the expression of the human P301L mutant tau in a transgenic mouse model. To favor the visualization of a relatively large proportion of different proteins on two-dimensional gels, the brain proteins were sequentially extracted in three fractions according to their solubility, namely, E1 (soluble proteins), E2 (intermediate soluble proteins), and E3 (less soluble proteins). The proteins of each fraction from six pairs of hemizygous P301L tau and WT control mice were first focused in 17-cm IPG strips depending on their isoelectric point (pI) and then resolved in the second dimension by their molecular mass on SDS-PAGE gels. Silver staining revealed reproducible two-dimensional protein patterns for each sequentially extracted fraction (Fig. 1). Differences between transgenic and WT mice were highlighted by the Proteomweaver software, which normalizes the overall spot intensities and then performs a comparison of every gel with every other gel. Protein spots that differed by >1.5-fold and were statistically significant by Student’s t test (p < 0.05) were considered for further investigation. Overall, we found 15 up-regulated and 22 down-regulated protein spots in P301L tau transgenic mice as compared with WT controls, including 4 up- and 4 down-regulated protein spots in fraction E1, 10 up- and 17 down-regulated protein spots in fraction E2, and 1 up- and 1 down-regulated protein spot in the last fraction, E3. After trypsinization, all but three of these differentially regulated protein spots were identified by MALDI-TOF/TOF mass spectrometry (Table 1). Several spots contained more than one protein, and some were identified as the same protein.

The majority of the regulated spots identified are related to...
either metabolism and mitochondrial respiration, oxidative stress, or synapse function. In the first category, we identified one spot as the 30-kDa subunit of NADH-ubiquinone oxidoreductase (electron transport chain complex I) and two spots as the ATP synthase D chain (complex V). All three spots were down-regulated as well as the metabolism-related spots, triosephosphate isomerase, a glycolytic enzyme, and the cytoplasmic malate dehydrogenase involved in the malate-aspartate shuttle providing a metabolic coordination between cytosol and mitochondria. In contrast, a spot identified as inorganic pyrophosphatase was up-regulated. Associated with oxidative stress, spots representing the antioxidant enzymes peroxiredoxin 6, perioredoxin 3 (thioredoxin-dependent peroxide reductase), glutathione S-transferase (GST) P2 and Mu1, and phospholipid hydroperoxide glutathione peroxidase were all down-regulated. In the last functional category, we found up-regulated spots related to synaptic function, such as the synaptic vesicle-associated proteins synapsin I, CDCrel-1, and septin 11, the axonal growth-related protein dihydropyrimidinase-related protein (DRP)>2, and another member of the dihydropyrimidinase family, DRP-3. Further differentially regulated spots (Table I) included stathmin, a microtubule-destabilizing protein; MSTI1, the murine homologue of hop (HSP70/HSP90 organizing protein); and growth factor receptor-bound protein 2 (GRB2), an adapter protein in signaling pathways. Therefore, P301L tau expression results in distinct modifications of the brain proteome, suggesting alterations in the mitochondrial electron transport chain, cellular antioxidant capacities, and synaptic properties.

**Fig. 3. Impaired depolarization and reduced mitochondrial complex I activity in P301L tau mice.** A, use of specific complex inhibitors reveals a significantly reduced depolarization of mitochondria from 12-month-old P301L tau mice after treatment with the complex I inhibitor rotenone (Rot) and the complex V inhibitor oligomycin (Oligo) (*, p < 0.05; **, p < 0.01 versus corresponding WT control mice, Student’s t test). A similar tendency was also found by inhibition of complex II with thenoyltrifluoroacetone, inhibition of complex III with antimycin (Ant), and inhibition of complex IV with NaN3. Two-way ANOVA reveals a significant effect of the transgene (p < 0.01) and individual complexes (p < 0.001), with no interaction between the two parameters. B–D, complex I activity in cerebral mitochondria from 12-month-old P301L tau mice and age-matched WT control mice. B, reduced NADH-ubiquinone oxidoreductase (NADH:DBQ) activity in mitochondria of P301L tau mice (*, p < 0.05 versus WT control mice, Student’s t test). C, unaltered NADH:HAR activity. D, complex I activity was normalized to the complex I content of the mitochondrial preparation and is given as DBQ/HAR ratio (*, p < 0.05 versus WT control mice, Student’s t test). E, unaltered complex IV activity. All values represent the means ± S.E. from n = 6–8 animals/group.
All experiments were performed in duplicates. Demonstrating a decrease in the total O2 concentration with time, O2 flux and consumption by mitochondria (bottom panel) was measured after addition of different agents (marked by arrows): malate/glutamate (mal/glu; state 4), ADP (state 3), FCCP, rotenone (rot), succinate (suc), and KCN. O2 consumption in freshly isolated cerebral mitochondria from 12-month-old mice (top panel) and 24-month-old mice (bottom panel), respectively. State 4 was measured after adding malate/glutamate. Then, ADP was added to measure state 3 respiration. After determining coupled respiration, FCCP was added, and respiration was measured in the absence of a proton gradient. To inhibit complex I activity, rotenone was added. Then, respiration was measured after the addition of succinate. Finally, complex IV activity and O2 consumption were inhibited by treatment with KCN. Two-way ANOVA reveals a significant effect of the transgene (p < 0.05) on coupled (state 3 and 4) and FCCP-induced uncoupled respiratory rates of mitochondria from 24-month-old P301L tau mice compared with age-matched WT controls by using the specific complex I substrates malate/glutamate. Thus, aged but not 12-month-old P301L tau mice exhibit a significant impairment of complex I-related respiration (*, p < 0.05 versus corresponding WT control, Student’s t-test), whereas respiratory rates after addition of the complex II substrate succinate are unchanged. Values represent the means ± S.E. from n = 4 animals/group (measurement of WT control and P901L tau in parallel). All experiments were performed in duplicates.

spots identified as the ATP synthase D chain, we looked at complex V levels in human FTDP-17 patient brains carrying the P301L tau mutation. Four P301L FTDP-17 brain and two control brain homogenates were examined by Western blot (Fig. 2A). We used the mitochondrial protein marker porin to control for variations in mitochondrial amounts. Normalization of complex V levels with porin levels showed a significant decrease in complex V levels in all P301L brain samples compared with control brains (Fig. 2B). Similar control complex V/porin percentages were found in three other control brain samples (data not shown). On average, we measured a 62.3% reduction of complex V levels in P301L tau transgenic mice compared with control brains. The decreased levels of complex V in human P301L FTDP-17 brains confirm the proteomics observation made in the P301L tau transgenic mice and suggest that the P301L mutant tau pathology potentially causes a specific mitochondrial dysfunction in humans as well as in mice.

**P301L Tau Mice Exhibit Mitochondrial Respiratory Defects**—We examined the metabolic capacity and function of cerebral mitochondria from P301L tau transgenic mice. Consistent with the down-regulation of subunits of mitochondrial electron transport chain complexes I and V, treatment with specific complex inhibitors showed a general reduction in mitochondrial depolarization of P301L tau brain cells compared with WT and specifically showed a significantly reduced depolarization after inhibition of complexes I and V (Fig. 3A). Using a direct measurement of complex I activity, we observed a significant reduction of NADH-ubiquinone oxidoreductase (NADH:DBQ) activity in mitochondria of 12-month-old P301L tau mice (Fig. 3B), whereas NADH:HAR activity (Fig. 3C) was not different, indicating that complex I content is similar in P301L tau and WT control mice. Thus, P301L tau mitochondria present a functional defect of complex I activity with a reduction of 30.75% as revealed after normalization of complex I activity with complex I content (Fig. 3D). In contrast, complex IV showed no differences in the cytochrome c oxidase activity between WT and P301L tau transgenic mice (Fig. 3E).

In addition, we determined the state 3 and state 4 respiration using substrates for complex I (glutamate/malate) (Fig. 4, A and B). State 3 respiration measures the capacity of mitochondria to metabolize oxygen and the selected substrate in the presence of a limited quantity of ADP, which is a substrate for the ATP synthase (complex V). State 4 respiration measures respiration when all ADP is exhausted, and it is associated with proton leakage across the inner mitochondrial membrane. Therefore, it represents a “basal-coupled” rate of respiration. Whereas state 3 and state 4 respiration remained unchanged with complex I substrates in 12-month-old P301L tau mice (Fig. 4B, top panel), a significantly reduced state 3 respiration could be observed in 24-month-old P301L tau mice (Fig. 4A and B, bottom panels), leading to a markedly reduced respiratory control ratio compared with age-matched WT mice (Fig. 5A). The respiratory control ratio provides a measure for the efficiency of coupling of the mitochondrial respiratory chain,
and subsequent counting of the mitochondria in proximal and distal parts of neurites in the CA1 region of the hippocampus also showed no variation between P301L tau and WT mice (Fig. 6B). These data suggest that mitochondrial dysfunction is not associated with reduced mitochondrial numbers or significant changes in transport of mitochondria along neurites.

**Increased Tau Pathology Causes Higher Oxidative Stress, Modified Lipid Peroxidation Levels, and Up-regulation of Antioxidant Enzyme Activities in P301L Tau Mice**—In P301L tau mice, these mitochondrial defects are associated with increased ROS formation because both staining with DHE for detection of superoxide anions and staining with H2DCF-DA for detection of cytosolic peroxides were increased (Fig. 7, A and B). Increased ROS levels could be detected already in 12-month-old P301L tau mice but were more pronounced and statistically significant in 24-month-old mice, correlating with the age-specific increase in tau pathology. As a measure of free radical damage to critical cellular components, levels of MDA as lipid peroxidation end product were determined. Despite increased ROS levels, basal levels of MDA were decreased in 24-month-old hemizygous P301L tau mice and more pronounced in homozygous mice, indicating that ROS levels are met by adequate antioxidant defenses in these mice (Fig. 7C). However, upon stimulation with ferric iron, increased MDA levels were formed in P301L tau mice (Fig. 7D). This effect was already observed in 12-month-old mice but was more pronounced and statistically significant in 24-month-old homozygous mice. Furthermore, basal and stimulated MDA levels remained unchanged in the cerebellum of 24-month-old hemi- and homozygous P301L tau and WT mice (data not shown). Because P301L tau is expressed at very low levels in the cerebellum (7), we can conclude that modifications in lipid peroxidation are specifically caused by the presence of the P301L tau protein. Hence, the presence of mutant tau impairs antioxidant defense under conditions of increased oxidative stress.

As a direct measure of antioxidant defense, activities of antioxidant enzymes were determined. Although no significant changes were observed in 12-month-old mice, 24-month-old homozygous P301L tau mice displayed increased activities of Cu,Zn-SOD and GR (Fig. 8, top and bottom), whereas the activity of glutathione peroxidase was not significantly increased (Fig. 8, middle). The increased enzyme activities may provide protection against ROS damage under basal conditions, but they are obviously not sufficient to eliminate lipid peroxidation damage caused by the in vitro stimulation of brain homogenates with ferric iron. It is important to note that modified lipid peroxidation levels and increased antioxidant enzyme activities are dependent on the levels of P301L tau pathology because these changes were only detected as significant in old homozygous P301L tau mice.

**Aβ Insult Causes Increased Membrane Potential Reduction in P301L Tau Mitochondria**—Extracellular Aβ treatment of PC12 cells has been shown to lead to a significant decrease in mitochondrial membrane potential (35). To investigate whether brain cells from P301L tau mice are more susceptible to Aβ, we measured the mitochondrial membrane potential of isolated cortical brain cells with and without Aβ treatment. Interestingly, the basal mitochondrial membrane potential was still conserved in cerebral cells from P301L tau mice. However, secondary insult with Aβ resulted in a higher reduction in membrane potential in P301L tau mitochondria than in WT mitochondria (Fig. 9A). Importantly, this effect is brain region-specific and therefore probably dependent on the presence of P301L tau because cells from cerebellum with very low P301L tau expression levels were not vulnerable to this damage (Fig. 9B). These data suggest a synergistic action of Aβ and tau pathology on mitochondrial function.
DISCUSSION

The P301L mutation of tau is one in a set of mutations implicated in FTDP-17 (36). This mutation reduces the ability of tau to interact with microtubules and promotes the assembly of tau into filaments in vitro. In our P301L tau transgenic mice, tau filaments start to accumulate at about 6 months of age, preceded by distinct hyperphosphorylation of tau (7, 20). Furthermore, the tau pathology causes specific behavioral deficits in the mice related to the amygdala, an area with prominent NFT formation (37).

Proteomics is becoming more and more widely used to study brain changes under physiological and pathological conditions such as in AD (38, 39). Considering the complexity of brain tissue, we adapted a sequential extraction method to separate the brain proteins according to solubility before proteomic analysis (40). This approach, followed by functional analysis of the P301L tau mice, suggests that tau accumulation, in the absence of massive NFT formation, induces a mitochondrial dysfunction. The down-regulation of nuclear encoded subunits of electron transport chain complexes I and V was accompanied by a reduced depolarization of mitochondria from 12-month-old P301L tau mice after treatment with the complex I inhibitor rotenone and the complex V inhibitor oligomycin. We could also demonstrate a direct decrease in complex I activity. At this age, the other mitochondrial respiratory chain complexes seemed to be able to compensate because the respiratory control ratio and mitochondrial membrane potential remained unchanged. However, following the increase of tau pathology with aging, this compensation is no longer sufficient, and mitochondria from 24-month-old P301L tau mice exhibited an impaired efficiency of coupling between the mitochondrial respiratory chain complexes, diminished capacity in electron transport, and a significant reduction in ATP levels. In particular, the reduction in state 3 respiration reflects a reduced capacity of mitochondria to metabolize oxygen and the complex I substrate in the presence of a limited quantity of ADP. Thus, there is also a clear complex I deficiency in the mitochondrial respiration at 24 months of age.

Our results correlate with previous studies on AD, suggesting partial mitochondrial uncoupling (41), modifications of mitochondrial encoded complex I subunit mRNA (42, 43), and reduction in protein levels of the 24- and 75-kDa subunits of complex I (11) as well as diminished ATP synthase (complex V) levels (10). As demonstrated in primates, complex I activity has been shown to be reduced with aging, which could potentially intensify complex I activity defects in the P301L tau mice (44). Furthermore, we could show a clear-cut reduction in levels of complex V in human P301L FTDP-17 brains as compared with control human brains. This important finding confirming the decrease in complex V identified twice in our proteomics analysis of the P301L tau mouse argues in favor of a potential mitochondrial dysfunction in human FTDP-17 patients. This result also emphasizes the relevance of our P301L tau mouse as a model of the human tau pathology.

Our proteomic analysis also revealed modifications in levels of triosephosphate isomerase, cytoplasmic malate dehydrogenase, and inorganic pyrophosphatase, implying a broader metabolic disorder possibly encompassing the glycolysis cycle. The glycolytic enzyme triosephosphate isomerase can bind to microtubules (45), and higher levels of nitrated triosephosphate isomerase have been found in AD brains (46). Consistent with an overall metabolic failure, several

FIG. 6. Unchanged number of mitochondria. A, measurement of the number of mitochondria using the cell-permeable mitochondrion-selective dye Mitotracker Green reveals no differences between P301L tau and WT mice in cerebrum. Values represent the means ± S.E. from n = 8 animals/group. B, immunostaining of mitochondria and microtubules in CA1 hippocampal brain sections with anti-porin (Cy3; red) and anti-tubulin antibodies (Cy2; green) again reveals no statistical difference in mitochondrial neuritic numbers in proximity or distal to the cell body between 18-month-old P301L tau and WT mice. Values represent the means ± S.D. from n = 4 animals/group, in which mitochondria were counted in four different neurites per animal. Scale bar, 50 μm.
Mitochondrial Dysfunction in P301L Tau Transgenic Mice

Fig. 7. Increased ROS production. A, increases in superoxide anion radicals determined by DHE oxidation. Fluorescence (in arbitrary units) normalized for protein content in brain cells from hemizygous P301L tau mice was measured after incubation of samples with DHE for 15 min. Two-way ANOVA: p < 0.01, effect of transgene; age and interaction were not significant. Bonferroni post hoc test: *, p < 0.05, WT versus hemizygous P301L tau mice. B, increases in cytosolic H2O2 determined by H2DCF oxidation. Fluorescence in brain cells from hemizygous P301L tau mice was measured after incubation of samples with H2DCF-DA for 15 min. Two-way ANOVA: p < 0.01, effect of transgene; age and interaction were not significant. Bonferroni post hoc test: *, p < 0.05, WT versus hemizygous P301L tau mice. C, reduced lipid peroxidation in P301L tau brains under basal conditions determined by MDA levels (nmol/mg protein). Two-way ANOVA: p < 0.01, effect of transgene; p < 0.05, age group; p < 0.05, interaction. Bonferroni post hoc test: ***, p < 0.001, WT versus homozygous P301L tau mice (P301L/P301L). D, increased lipid peroxidation under stimulated conditions in 24-month-old homozygous P301L tau mice. Formation of MDA (nmol/mg protein) in brain homogenates after a 30-min incubation with FeCl3 is increased in samples from P301L tau mice. Two-way ANOVA: p < 0.05, effect of transgene; age and interaction were not significant. Bonferroni post hoc test: *, p < 0.05, controls versus homozygous P301L tau mice. All values represent means ± S.E. from n = 6–9 animals/group (except for 12-month-old homozygous animals, n = 3).

reports using positron emission tomography revealed reduced glucose metabolism in AD and frontotemporal dementia brains (12, 13, 47–49). Notably, high levels of phosphorylated tau have been linked to glucose hypometabolism in mild cognitively impaired patients (50).

Together, this evidence supports a role of tau pathology in mitochondrial and metabolic dysfunction. However, it remains unclear how tau accumulation mediates these changes. Overexpression of WT tau in cell culture caused impairment of plus end-directed transport, resulting in a reduction of mitochondria levels in the neurites (51). Although we cannot exclude the possibility of this occurring in the P301L tau mice, the number of mitochondria in neurites counted in proximity or distally to the cell body did not vary significantly compared with WT numbers. Furthermore, the total amount of mitochondria remained unchanged as measured in brain cells of transgenic compared with control mice. This suggests that either P301L tau induces a different pathological mechanism than overexpressed WT tau or that tau action on mitochondria transport in cell culture cannot be extrapolated over to the mouse model. Consistent with our findings, similar numbers of mitochondria were reported in NFT-bearing and non-NFT-bearing cells in AD (52). Alternatively, tau accumulation could have direct repercussions on the mitochondria because the accumulation of increasingly insoluble ATP synthase a-chain together with NFTs has been shown in AD brains, whereas detergent soluble levels were reduced (53). Overall, it is important to note that the mitochondrial pathology in the P301L tau mice observed in this study is unlikely to be a direct consequence of tau hyperphosphorylation. Indeed, the transgene levels of expression in these mice are relatively low (7), and depletion of ATP solely due to tau hyperphosphorylation would be improbable.

We furthermore demonstrate that accumulation of P301L tau causes significant modifications in the oxidative state of the brain. ROS measurements revealed increased levels of cytosolic H2O2 and superoxide anion radicals in 2-year-old P301L tau mice. These increased ROS levels may be a direct consequence of reduced complex I activity in P301L tau mice because inhibition of complex I can lead to increased superoxide formation (54). The increased activity of Cu,Zn-SOD measured in P301L tau mice should ameliorate the accumulation of superoxide but also gives rise to H2O2, which is then insufficiently processed by glutathione peroxidase, leading to accumulation of peroxides. Accordingly, the relative increase in H2O2 in P301L tau mice was much more pronounced than the increase in superoxide radicals. Somewhat unexpectedly, along with increased tau pathology, we observed decreased levels of the lipid peroxidation product MDA as a marker for ROS damage to cellular membranes in old homozygous P301L tau mice, despite increased levels of ROS. One potential explanation for this discrepancy could be that the cells affected by lipid peroxidation are removed by apoptosis, although we could not detect major differences in levels of apoptotic cells detected by terminal deoxynucleotidyl transferase-mediated nick end labeling staining (data not shown). Because several steps lead from ROS accumulation to lipid peroxidation damage, another possibility would be that the up-regulation of antioxidant activities of Cu,Zn-SOD and GR in P301L tau mice may intercept ROS before they can critically damage membranes. As previously reported, rising Cu,Zn-SOD and GR activities in aged mouse...
brains can protect against lipid peroxidation (55). Furthermore, SOD can prevent lipid peroxidation both in vitro and in vivo (56–60). Similarly, increased GR activity in P301L tau mice may protect against accumulation of MDA by increasing levels of the antioxidant reduced glutathione. In several experimental models, increased levels of reduced glutathione were associated with lower levels of lipid peroxidation products and vice versa (61, 62). Upon in vitro stimulation, however, higher levels of MDA were formed in homozygous P301L tau brain homogenates. Obviously, the increased activities of Cu,Zn-SOD and GR were not sufficiently protective under these conditions. This may be explained by a relative lack in glutathione peroxidase activity because the accumulation of H2O2 observed in brains from P301L tau mice combined with the exogenously added ferric iron can lead to increased formation of hydroxyl radicals via Haber-Weiss and Fenton reactions. Reports on lipid peroxidation in brains from patients with tauopathies are inconsistent. Although increased levels of the lipid peroxidation product 4-hydroxynonenal were found in patients with progressive supranuclear palsy (63), and tau was co-localized with MDA immunoreactivity in AD patients (64), another study reported increased lipid peroxidation products specifically in AD patients, but not in patients with frontotemporal dementia (65). Therefore, tau pathology may not be associated inevitably with lipid peroxidation processes in human brain tissue, consistent with our observations in P301L tau mice. Most studies have reported an up-regulation of antioxidant enzyme activities in AD (66). These changes were most pronounced in brain regions that are severely affected by AD pathology (66–68).

![Fig. 8](image-url)

**Fig. 8.** Altered levels in detoxifying enzymes. Top, increased Cu,Zn-SOD activity in 24-month-old homozygous P301L tau mice. Two-way ANOVA: effect of transgene was not significant; p < 0.05, age group; p < 0.05, interaction. Bonferroni post hoc test: *, p < 0.05, controls versus homozygous P301L tau mice. Middle, glutathione peroxidase activity. Two-way ANOVA: p < 0.05, effect of transgene; age group and interaction were not significant. Bottom, increased GR activity in 24-month-old homozygous P301L tau mice. Two-way ANOVA: p < 0.05, effect of transgene; age group and interaction were not significant. Bonferroni post hoc test: *, p < 0.05, controls versus homozygous P301L tau mice. Values represent means ± S.E. from n = 6–9 animals/group (except for 12-month-old homozygous animals, n = 3).

![Fig. 9](image-url)

**Fig. 9.** Brain region-specific decrease of membrane potential after secondary insult with 50 nM Aβ. Aged, aggregated preparations of Aβ1–42 were given to brain cells as secondary insult. An increased reduction of Δψm was observed with the addition of Aβ to cerebral cells (A) (*, p < 0.05 versus WT control mice, Student’s t test), but not with cerebellar cells (B) from 12-month-old P301L tau mice. Two-way ANOVA reveals a significant effect of the transgene (p < 0.05) on changes of mitochondrial membrane potential in cerebral cells. Values represent the means ± S.E. from n = 6–7 animals/group.

Our proteomic analysis also suggests changes in cellular antioxidant mechanisms as shown by variations in spots representing the antioxidant enzymes periredoxin 3, periredoxin 6, GST P2 and Mu1, and phospholipid hydroperoxide glutathione peroxidase. Peroxiredoxin reduces peroxides including H2O2, GST catalyzes the conjugation of reduced glutathione to a large number of molecules, and phospholipid hydroperoxide glutathione peroxidase directly reduces peroxidized phospholipids in membranes (69). Although all these protein spots were down-regulated in the P301L tau mouse, this does not necessarily reflect enzyme activities. Besides, under oxidative conditions, these antioxidant enzymes are prone to oxidative modifications represented by a set of distinct spots on two-dimensional gels as suggested for periredoxin, which undergoes overoxidation. Interestingly, AD brains show decreased GST activity (70) and GST Omega1 mRNA levels in AD (43), and single nucleotide polymorphisms in GST Omega1 are associated with age at onset in AD (43).

Hence, both our functional and proteomic data indicate a complex regulation and potential malfunction of the cellular...
antioxidant defense mechanisms in response to increased ROS levels in this mouse model. Because mitochondrial dysfunction appears prior to oxidative stress, this suggests that it is probably the initiating factor. However, we can speculate that both mitochondrial dysfunction and oxidative stress act in synergy, creating a vicious cycle. Indeed, increases in ROS and antioxidant enzyme dysfunction could affect the integrity of the mitochondrial and, in particular, the electron transport chain (35). Furthermore, glutathionylation of complex I in oxidative conditions leads to increased superoxide production (71). Another possible consequence of higher oxidative stress levels could be an acceleration of tau pathology (72, 73). Moreover, tau can be readily oxidized by \( \text{H}_2\text{O}_2 \) to form disulfide-linked species that manifest reduced propensity to promote microtubule assembly (74). Oxidized tau then becomes a substrate of the thioredoxin reductase and glutathione/glutaredoxin reductase systems (74, 75). Thereby, we can speculate that the accumulation of oxidized P301L tau might overload these antioxidant regenerating systems, causing further oxidative stress.

Results from our proteomic study further suggest a potential synaptic dysfunction because we found an up-regulation of a series of synapse-related proteins. The identified DRP-2 is known to promote axonal growth by interaction with the tubulin heterodimer and has also been shown to induce neurite formation (76, 77). Synapsin I is thought to regulate the reserve pool of synaptic vesicles (78). The septin member CDCrel-1 is found mainly in inhibitory presynaptic terminals and inhibits A 

Sections in various chaperone levels in AD brain (87). In addition, although advanced stages of AD are associated with synaptic loss, an initial increase in synaptic protein levels in deh, although we can speculate that both P301L and AD pathology. Although it is uncertain exactly how tau mechanistically affects synapses, we can postulate that the mutant tau acts either by causing increased microtubule stability and axonal transport or by inhibiting energy production through complex I in the synapses. Indeed, a reduction in the activity of complex I by only 25% has been shown to impair energy metabolism in synaptic mitochondria (84), whereas at least a 72% reduction in complex I activity is needed before energy metabolism is impaired in non-synaptic mitochondria (85). In this study, our mitochondrial isolation does not include synaptic mitochondria. It would be interesting to measure complex I activity and mitochondrial respiration in a pure synaptosomal mitochondrial preparation.

In addition to the three major categories (metabolism-related proteins, antioxidant enzymes, and synaptic proteins), we could identify, by proteomics, several other proteins modified by the presence of the P301L tau and potentially linked to AD pathology. The up-regulated MST11 mediates assembly of HSP70/HSP90 (86). A proteomic study has shown modifications in various chaperone levels in AD brain (87). In addition, levels of HSP alpha-crystallin, HSP27, and HSP60 were found to be increased in tauopathies with glial pathology (88). Decreased in the P301L tau mouse brain proteome pattern, GRB2 is an adapter protein that is involved in the activation of the mitogen-activated protein kinase signaling pathway. Interestingly, AD brains show higher amounts of GRB2 than control brains (89, 90). Levels of the microtubule-stabilizing protein stathmin have been found to be negatively correlated with NFT numbers in AD neocortex (91) and were also down-regulated in the P301L tau mice.

Finally, our data from the proteomic and functional study of the P301L tau transgenic mouse should help to better distinguish between the respective pathological actions of A\( \beta \) and tau protein. Numerous studies indicate that A\( \beta \) also causes oxidative stress and mitochondrial malfunction (35, 92–94). In particular, A\( \beta \) has been shown to generate free radicals in vitro (95) and reduces mitochondrial respiration through inhibition of cytochrome c oxidase activity (35, 96). We show here that A\( \beta \) causes increased reduction of mitochondrial membrane potential in P301L tau mouse cerebrum compared with wild-type cerebrum. Importantly, this is not observed in the cerebellum of P301L tau mice, a brain area with very low levels of transgenic tau. This could partially explain why injection of fibrillar A\( \beta \) peptide into the hippocampus of P301L tau mice accelerated NFT formation in the amygdala, in line with the amyloid cascade hypothesis (20). Therefore, both tau and A\( \beta \) accumulation probably act in synergy on oxidative stress and mitochondrial dysfunction.

In conclusion, our study increases understanding of the pathological consequences of tau alone, suggesting that not only A\( \beta \) but also tau accumulation acts on the metabolism of the brain and the oxidative conditions in AD. This implies that it will be important to address the treatment and/or removal of both A\( \beta \) and tau pathology to efficiently treat AD patients.

Acknowledgments—We thank Dr. Robert Layfield for helpful suggestions; Dr. Peter Gehrig for excellent assistance with mass spectrometry; the Functional Genomics Center Zürich for providing access to the MALDI-TOF/TOF apparatus, GelPix robot, and Proteinweaver software; Ilka Siebels for excellent technical assistance; and James Opoku for animal care.

REFERENCES

1. Lee, V. M., Goedert, M., and Trojanowski, J. Q. (2001) Annu. Rev. Neurosci. 24, 1121–1159
2. Gotz, J., Strefler, J. R., David, D., Schild, A., Hoerndli, F., Pennanen, L., Kurotsinska, P., and Chen, F. (2004) Mol. Psychiatry 9, 664–683
3. Pooka, P., Bird, T. D., Wijsman, E., Nemens, E., Garruto, R. M., Anderson, L., Hedges, A., Wiedeholt, W. C., Raskind, M., and Schellenberg, G. D. (1999) Ann. Neurol. 45, 815–825
4. Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., Hackett, J., Adamson, J., Lin, S., Dickson, D., Davies, W., Petersen, R. C., Stevens, M., de Graaff, E., Wauters, E., van Baren, J., Hillebrand, M., Jooose, M., Kwon, J. M., Nowotny, P., Che, L. K., Norton, J., Morris, J. C., Reed, L. A., Tanasescu, L., Basun, H., Hannestad, L., Nystedt, M., Fahn, S., Dark, F., Tannenberg, T., Dod, P., Hansen, R., Kwock, J., Schofield, P. R., Andreasen, A., Snowden, J., Cru,ird, D., Neary, D., Owen, F., Oostra, B. A., Hardy, J., Gaite, A., van Swieten, J., Mann, D., Lynch, T., and Heutink, P. (1998) Nature 393, 702–705
5. Spillantini, M. G., Murrell, J. R., Goedert, M., Farlow, M. R., Klug, A., and Ghezzi, B. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7774–7778
6. Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, P. M., Baker, M., Yu, X., Duff, K., Hardy, J., Corral, A., Lin, W. L., Yen, S. H., Dickson, D. W., Davies, P., and Hutton, M. (2000) Nat. Genet. 25, 402–405
7. Gotz, J., Chen, F., Barmettler, R., and Nitsch, R. M. (2001) J. Biol. Chem. 276, 529–534
8. Mattson, M. P., Pedersen, D. A., Deane, C., Willmore, B. J., and Beal, M. F. (1994) Ann. N. Y. Acad. Sci. 718, 154–175
9. Mutisya, E. M., Bowling, A. C., and Beal, M. F. (1994) J. Neurochem. 63, 2179–2184
10. Schagger, H., and Ohm, T. G. (1995) Eur. J. Biochem. 227, 916–921
11. Kim, S. H., Vilohnskis, R., Cairns, N., Fountoulakis, M., and Lubec, G. (2001) Life Sci. 67, 2741–2750
12. Jagust, W. J., Seab, J. P., Huesman, R. H., Valk, P. E., Mathis, C. A., Reed, B. R., Coxson, P. G., and Budinger, T. F. (1991) J. Cereb. Blood Flow Metab. 11, 323–330
13. Santos, P., De Bleecker, J., Goethals, P., Strijkmars, K., Lemeshina, I., Schufter, G., Dierckx, R., and De Reuck, J. (2001) Eur. Neurol. 45, 19–27
14. Shoffner, J. M., Brown, M. D., Torroni, A., Lott, M. T., Cabell, M. F., Mirra, S. S., Beal, M. F., Yang, C. C., Gearing, M., Salvo, R., Watts, E. L., Junes, J. L., Hansen, L. A., Crain, B. J., Fayed, M., Reedk, C. L., and Wallace, D. C. (1998) Genomics 17, 171–184
15. Corral-Debrinski, M., Horton, T., Lott, M. T., Shoffner, J. M., McKee, A. C., Beal, M. F., Graham, B. H., and Wallace, D. C. (1994) Genomics 23, 471–476
16. Coskun, P. P., Beal, M. F., and Wallace, D. C. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 10726–10731
17. Hajasnikhamadreza, I., and Bramer, M. (1999) Neurosci. Lett. 112, 333–337
